AIM
BIB icon

Axiom Investment Management’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Axiom Investment Management’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.08K Buy
+50
New +$4.14K ﹤0.01% 353

Other funds holding BIB

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return
KFS
Kaizen Financial Strategies Campbell, California $236M AUM 28.3% 1-Year Est. Return
PWM
Palumbo Wealth Management Great Neck, New York $410M AUM 32.56% 1-Year Est. Return
CAG
Csenge Advisory Group Clearwater, Florida $2.18B AUM 16.73% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Axiom Investment Management's BIB Position: Q1 2026 in Review

Axiom Investment Management opened a new position in ProShares Ultra NASDAQ Biotechnology (BIB) in Q1 2026: 50 shares worth $4.08K. The stake represents ﹤0.01% of the portfolio and ranks #353 among its holdings.

23 funds tracked by Wall St. Rank hold BIB as of Q1 2026.

  • Axiom Investment Management held 50 shares of ProShares Ultra NASDAQ Biotechnology worth $4.08K as of Q1 2026.
  • ProShares Ultra NASDAQ Biotechnology was a new Axiom Investment Management position in Q1 2026.
  • ProShares Ultra NASDAQ Biotechnology made up ﹤0.01% of Axiom Investment Management's portfolio in Q1 2026, its #353 holding.
  • 23 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2026.

Based on Axiom Investment Management's 13F filing for Q1 2026, filed 26 May 2026.